Log in

NASDAQ:ARAVAravive Stock Price, Forecast & News

-0.15 (-2.53 %)
(As of 04/8/2020 06:00 AM ET)
Today's Range
Now: $5.79
50-Day Range
MA: $6.56
52-Week Range
Now: $5.79
Volume76,379 shs
Average Volume150,527 shs
Market Capitalization$86.94 million
P/E RatioN/A
Dividend YieldN/A
Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARAV



Sales & Book Value

Annual Sales$4.75 million
Book Value$4.71 per share


Net Income$-18,220,000.00


Market Cap$86.94 million
Next Earnings Date5/13/2020 (Estimated)

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have increased by 16.0% and is now trading at $5.79. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aravive?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive Inc (NASDAQ:ARAV) announced its earnings results on Friday, March, 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.17. View Aravive's earnings history.

What price target have analysts set for ARAV?

5 brokerages have issued twelve-month price targets for Aravive's stock. Their forecasts range from $15.00 to $31.00. On average, they anticipate Aravive's share price to reach $26.00 in the next year. This suggests a possible upside of 349.1% from the stock's current price. View analysts' price targets for Aravive.

Has Aravive been receiving favorable news coverage?

Media coverage about ARAV stock has been trending very negative this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aravive earned a news impact score of -3.3 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAravive.

Are investors shorting Aravive?

Aravive saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 505,000 shares, an increase of 21.0% from the February 13th total of 417,400 shares. Based on an average daily trading volume, of 205,100 shares, the short-interest ratio is presently 2.5 days. Approximately 5.9% of the shares of the stock are sold short. View Aravive's Current Options Chain.

Who are some of Aravive's key competitors?

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Inovio Pharmaceuticals (INO), Athersys (ATHX), Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Aerie Pharmaceuticals (AERI), DURECT (DRRX), Precision BioSciences (DTIL), Novavax (NVAX), Roku (ROKU) and AIM ImmunoTech (AIM).

Who are Aravive's key executives?

Aravive's management team includes the following people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Vinay Shah, Chief Financial Officer
  • Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $5.79.

How big of a company is Aravive?

Aravive has a market capitalization of $86.94 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe. View additional information about Aravive.

What is Aravive's official website?

The official website for Aravive is http://www.aravive.com/.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 4/8/2020 by MarketBeat.com Staff

Featured Article: What is a resistance level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel